Azienda Universitaria Ospedaliera Consorziale Policlinico Bari

At Azienda Universitaria Ospedaliera Consorziale Policlinico Bari, the University Cardiology team is conducting research in cardiovascular medicine focused on heart failure and obesity. These studies are designed to assess whether new treatment approaches can better reduce heart-related events and improve outcomes for people living with complex chronic heart disease.

• Heart failure with preserved or mildly reduced ejection fraction
• Obesity as a major factor in cardiovascular risk
• Testing new therapies to lower hospitalizations and cardiovascular death

This work reflects a strong interest in improving both symptom control and long-term protection for patients with overlapping cardiac and metabolic conditions.

The site is also involved in hematology research on aggressive B-cell acute lymphoblastic leukemia, including forms linked to Philadelphia chromosome abnormalities. The studies aim to evaluate whether newer treatment combinations can improve survival while maintaining an acceptable safety profile in children, adolescents, and young adults.

• Philadelphia chromosome positive B-cell acute lymphoblastic leukemia
• ABL-class Philadelphia chromosome-like B-cell acute lymphoblastic leukemia
• Evaluating treatment effectiveness and safety in newly diagnosed disease

This research focuses on improving outcomes for patients with high-risk blood cancers through more targeted and coordinated treatment strategies.

Clinical trials in metabolic disease at this hospital are centered on obesity, overweight, and type 2 diabetes. The main goal is to test whether new therapies can support meaningful weight management and help address the broader health burden associated with metabolic disorders.

• Obesity and overweight
• Type 2 diabetes
• Evaluating new approaches for weight reduction and metabolic control

These studies are especially relevant for patients whose weight-related conditions may also increase the risk of cardiovascular complications.

In the field of oncology, the research program includes studies in advanced or metastatic extrapulmonary neuroendocrine carcinoma. The trials are designed to determine whether adding a new investigational therapy to standard chemotherapy can improve overall survival for patients with this difficult-to-treat cancer.

• Advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Testing new treatment combinations in solid tumors
• Improving survival in previously untreated advanced cancer

This area highlights the site’s broader commitment to developing better cancer treatments through clinical research.